Pancreatic Cancer Development: Genetic and Immune Regulation

摘要（总体）： 胰腺导管腺癌（PDAC）是一种致命的疾病，其发展机制仍然存在 不完全理解。有证据表明，胰腺癌可能是由腺泡细胞经历 称为腺泡到导管化生 (ADM) 或从导管细胞产生胰腺上皮内的过程 肿瘤（PanIN）。突变或突变组合如何促进 PDAC 发育以及其作用 该过程中的炎症仍不清楚。此外，免疫细胞、癌症之间的相互作用 相关成纤维细胞 (CAF) 和癌细胞可以促进 PDAC 的发育和进展，但 肿瘤微环境（TME）中细胞之间的信号传导如何影响干细胞仍有待了解 细胞区室（“干性”）被认为是 PDAC 发育的基础并促进免疫逃避。因此， 关于控制 PDAC 发展的基本机制的多个问题仍然存在。 为了应对这些挑战，我们优秀且高度互动的团队将识别遗传和基质（免疫） 使用创新技术调节 PDAC 的发生和进展的相互作用和途径 小鼠模型和基于人体组织的方法。我们提出三个项目来解决以下总体问题 目标： 1. 识别起源细胞并解构 PDAC 启动的遗传途径 2. 发现与上皮细胞和 CAF 相互作用促进胰腺癌的免疫信号 发展与干性 3. 研究肿瘤遗传学对 PDAC 免疫生物学和巨噬细胞靶向反应的影响 免疫疗法 这些项目的工作将通过行政和生物统计核心（A）进行组织并授权 由两个研究核心组成，重点关注人体组织采购（核心 B）和高维成像的使用 测量组织中的细胞和信号传导相互作用（CODEX；核心 C）。 P01 的参与研究人员领导的团队多年来一直富有成效地合作，并拥有 生成了令人信服的初步数据，支持解开遗传和免疫信号传导的潜力 PDAC 发展的机制，并为 PDAC 开发新的免疫治疗策略， 令人沮丧的是，它已被证明对免疫疗法具有抵抗力。 我们的研究应该广泛影响胰腺癌生物学，重要的是，阐明相互的相互作用 免疫和非免疫区室（上皮细胞，CAF）之间在塑造肿瘤微环境中的作用 在疾病演变过程中。加速发现新的早期诊断或预防策略 疾病或晚期 PDAC 的治疗方法。

Abstract (Overall): Pancreatic Ductal Adenocarcinoma (PDAC) is a deadly disease whose mechanisms of development remain incompletely understood. Evidence suggests that pancreatic cancers may arise from acinar cells undergoing a process called acinar to ductal metaplasia (ADM) or from ductal cells to give rise to Pancreatic Intraepithelial Neoplasias (PanINs). How mutations or combinations of mutations promote PDAC development and the role of inflammation in the process still remains unclear. Moreover, interactions between immune cells, cancer- associated fibroblasts (CAFs) and cancer cells can promote PDAC development and progression, but much remains to be learned about how signaling between cells in the tumor microenvironment (TME) affects the stem cell compartment (`stemness') thought to underlie PDAC development and promotes immune evasion. Thus, multiple questions about fundamental mechanisms governing PDAC development persist. To address these challenges, our superb and highly interactive team will identify genetic and stromal (immune cells and CAFs) interactions and pathways that regulate the inception and progression of PDAC using innovative mouse models and human tissue-based approaches. We propose three Projects to address the following overall aims: 1. Identify the originating cell(s) and deconstruct genetic pathways underlying PDAC initiation 2. Discover immune signals that cross-talk with epithelial cells and CAFs to promote pancreas cancer development and stemness 3. Investigate the impact of tumor genetics on PDAC immunobiology and response to macrophage-targeted immunotherapy Effort on these projects will be organized through an Administrative and Biostatistics Core (A) and empowered by two Research Cores, focused on human tissue procurement (Core B), and use of high-dimensional imaging to measure cell and signaling interactions in tissues (CODEX; Core C). The participating investigators on this P01 lead teams that have collaborated productively for years and have generated compelling preliminary data that support the potential for unraveling the genetic and immune signaling mechanisms underlying PDAC development, and developing new immunotherapeutic strategies for PDAC, which has proven frustratingly resistant to immuno-based therapies. Our studies should broadly impact pancreas cancer biology and importantly, elucidate the reciprocal interactions between immune and non-immune compartments (epithelial, CAFs) in shaping the tumor microenvironment during disease evolution. accelerate discovery of novel diagnostic or preventive strategies for early-stage disease, or therapeutics for advanced PDAC.